Anticorps Recombinant de lapin anti-DNAJB8

DNAJB8 Recombinant Antibody for WB, Indirect ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, rat, souris

Applications

WB, Indirect ELISA

Conjugaison

Non conjugué

CloneNo.

251752B7

N° de cat : 86763-3-PBS

Synonymes

DJ6

---

Galerie de données de validation

• 

  WB analysis using 86763-3-RR (same clone as 86763-3-PBS)

  Various lysates were subjected to SDS PAGE followed by western blot with 86763-3-RR (DNAJB8 antibody) at dilution of 1:10000 incubated at room temperature for 1.5 hours. This data was developed using the same antibody clone with 86763-3-PBS in a different storage buffer formulation.

---

Informations sur le produit

86763-3-PBS cible DNAJB8 dans les applications de WB, Indirect ELISA et montre une réactivité avec des échantillons Humain, rat, souris

• Réactivité: Humain, rat, souris
• Hôte / Isotype: Lapin / IgG
• Clonalité: Recombinant
• Type: Anticorps
• Immunogène: DNAJB8 Protéine recombinante Ag10899
• Nom complet: DnaJ (Hsp40) homolog, subfamily B, member 8
• Masse moléculaire calculée: 232 aa, 26 kDa
• Poids moléculaire observé: 26 kDa
• Numéro d’acquisition GenBank: BC029521
• Symbole du gène: DNAJB8
• Identification du gène (NCBI): 165721
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par protéine A
• Tampon de stockage: PBS only
• Conditions de stockage: Store at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

DNAJB8, a member of the DNAJ/HSP40 family of proteins, plays a crucial role in regulating chaperone HSP70 activity. It is known for its ability to suppress the aggregation of polyglutamine proteins through its C-terminal tail. Furthermore, DNAJB8 has been shown to inhibit TP53 through ubiquitin degradation in human colon cancer by directly interacting and upregulating MDR1, leading to increased oxaliplatin resistance. High levels of DNAJB8 in both colon tissues and serum are correlated with worse overall survival of colon cancer patients, suggesting that DNAJB8 level in serum sEV may serve as a potential biomarker for colon cancer and a promising therapeutic target for oxaliplatin-resistant cancer.

{{ptg:RelatedPrimaryAntibodies}}